Loading clinical trials...
Loading clinical trials...
Pilot Study of the Efficacy and Safety of CD38 Targeted Chimeric Antigen Receptor Engineered T-Cells in the Treatment of CD38 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions
Interventions
CART-38
Locations
1
China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
July 1, 2017
Primary Completion Date
December 31, 2021
Completion Date
December 31, 2023
Last Updated
April 24, 2020
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT06484062
NCT04628026
Lead Sponsor
The First Affiliated Hospital of Soochow University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions